Economic Benefits of Treating High-Risk Hypertension with Angiotensin II Receptor Antagonists (Blockers)
@article{Coca2008EconomicBO, title={Economic Benefits of Treating High-Risk Hypertension with Angiotensin II Receptor Antagonists (Blockers)}, author={A. Coca}, journal={Clinical Drug Investigation}, year={2008}, volume={28}, pages={211-220} }
Hypertension is one of the leading risk factors for cardiovascular disease and represents a major health and economic burden. Most patients with high-or very high-risk hypertension have multiple cardiovascular risk factors with or without accompanying subclinical organ damage or established cardiovascular or renal disease. Patients with severe hypertension or with moderate hypertension and one to two additional risk factors have absolute 10-year risks of cardiovascular disease of 21–30% and 15… Expand
Topics from this paper
15 Citations
Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care.
- Medicine
- Swiss medical weekly
- 2013
- 10
- PDF
Hypertension treatment in a section of the prescribed management benefit market in South Africa
- Medicine
- 2012
Evolutionary cost analysis of valsartan initiation among patients with hypertension: a time series approach
- Medicine
- Journal of medical economics
- 2012
- 8
Upregulation of Renin Angiotensin Aldosterone System (RAAS) by Methylglyoxal: Role in Hypertension
- Medicine
- 2013
Role of Neuronal Nitric Oxide Synthase on Cardiovascular Functions in Physiological and Pathophysiological States.
- Medicine
- Nitric oxide : biology and chemistry
- 2020
References
SHOWING 1-10 OF 52 REFERENCES
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
- Medicine
- The New England journal of medicine
- 2001
- 3,860
- PDF
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
- Medicine
- Swiss medical weekly
- 2006
- 8
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
- Medicine
- The Lancet
- 2004
- 1,862
- PDF
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
- Medicine
- The New England journal of medicine
- 2001
- 5,184
- PDF
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
- Medicine
- The Lancet
- 2002
- 5,291
- PDF
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
- Medicine
- Clinical therapeutics
- 2003
- 48
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
- Medicine
- The New England journal of medicine
- 2001
- 3,039
Combination Angiotensin Receptor Blocker/Hydrochlorothiazide as Initial Therapy in the Treatment of Patients With Severe Hypertension
- Medicine
- Journal of clinical hypertension
- 2004
- 36
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension
- Medicine
- Current medical research and opinion
- 2006
- 8